Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.
Gordon C WeirMario R EhlersKristina M HarrisSai KanaparthiAlice LongDeborah PhippardLia J WeinerBrett JepsonJames G McNamaraMaria KoulmandaTerry B Stromnull nullPublished in: Pediatric diabetes (2018)
AAT was well tolerated and safe in subjects with new-onset type 1 diabetes. Weekly doses of AAT greater than 90 mg/kg may be necessary for an optimal therapeutic effect.